WASHINGTON, June 24 (Reuters) - Novo Nordisk chief

executive Lars Jorgensen's testimony before the U.S. Senate

health committee on U.S. prices for weight loss drugs Ozempic

and Wegovy will take place on Sept. 24, committee chairman

Senator Bernie Sanders said on Monday.e

The Senate Committee on Health, Education, Labor, and

Pensions had said earlier this month that Jorgensen agreed to

testify voluntarily in a hearing but did not specify a date.

"The Committee looks forward to Mr. Jorgensen answering a

very simple question: Why does he think it's acceptable to

charge Americans up to 10 or 15 times more for Ozempic and

Wegovy than people in Europe and other major countries?" Sanders

said in a statement.